



Hans-Georg Wirsching

Contact

Hans-Georg Wirsching

Publications (11)

Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. *BMC cancer* 2024; 24:82.

Padevit L, Vasella F, Friedman J, Mutschler V, Jenkins F, Held U, Rushing E, Wirsching H, Weller M, Regli L, Neidert M. A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up. *Front Oncol* 2023; 13:1279933.

Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. *Neurooncol Pract* 2023; 11:132-141.

Medici G, Freudenmann L, Velz J, Wang S, Kapolou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitberger A, Silgner M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. *Acta Neuropathol* 2023; 146:173-190.

German Consortium on Aggressive Meningiomas (KAM), Ratliff M, Neidert M, Wirsching H, Harter P, Unterberg A, Herold-Mende C, Jungwirth G, Etminan N, Lamszus K, Westphal M, Hänggi D, Jungk C, Mawrin C, Platten M, Snuderl M, Sahm F, von Deimling A, Preusser M, Weller M, Wick W, Acker T, Reifenberger G, Jones D, Pfister S, Frank S, Hench J, Brandner S, Aldape K, Sen C, Golfinos J, Serrano J, Stein M, Dohmen H, Reuss D, Dogan H, Patel A, Blume C, Euskirchen P, Sill M, Schrimpf D, Berghoff A, Sievers P, Hielscher T, Stichel D, Reinhardt A, Suwala A, Grady C, Jones T, Bridges L, Greenway F, Leu S, Jaunmuktane Z, Schittenhelm J, Ketter R, Bewerunge-Hudler M, Rushing E, Ricklefs F, Baumgarten P, Wefers A, Maas S. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *J Clin Oncol* 2021; 39:3839-3852.

Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). *Swiss Med Wkly* 2021; 151:w20501.

Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. *Clin Cancer Res* 2020; 27:179-188.

Sievers P, Etminan N, Ratliff M, Herold-Mende C, Pfister S, Jones D, Weller M, Harter P, Wick W, Preusser M, von Deimling A, Westphal M, Lamszus K, Reifenberger G, Hielscher T, Schrimpf D, Stichel D, Reuss D, Berghoff A, Neidert M, Wirsching H, Mawrin C, Ketter R, Paulus W, Sahm F. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathol* 2020; 140:409-413.

Paramasivam N, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister S, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Bewerunge-Hudler M, Schick M, Hübschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers A, Jones D, Gu Z, Werner J, Uhrig S, Wirsching H, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathol* 2019; 138:295-308.

Katz L, Baumgarten P, Herold-Mende C, Wick W, Harter P, Weller M, von Deimling A, Snuderl M, Sen C, Wirsching H, Neidert M, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos J, Reuss D, Sahm F. Loss of histone H3K27me₃ identifies a subset of meningiomas with increased risk of recurrence. *Acta Neuropathol* 2018; 135:955-963.

Wirsching H, Morel C, Gmür C, Neidert M, Baumann C, Valavanis A, Rushing E, Krayenbühl N, Weller M. Predicting outcome of epilepsy after meningioma resection. *Neuro Oncol* 2015; 18:1002-10.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch